1 / 21

Stroke and Alzheimer’s Disease Dr Jackie Hunter

Stroke and Alzheimer’s Disease Dr Jackie Hunter. Senior Vice-President Neurology & Gastrointestinal Centre of Excellence for Drug Discovery GSK Harlow. Outline of Talk. General Comments on Process Stroke (chapter written by Eduardo Sabate & Sunil Wimalaratna)

sidonie
Download Presentation

Stroke and Alzheimer’s Disease Dr Jackie Hunter

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Stroke and Alzheimer’sDiseaseDr Jackie Hunter Senior Vice-President Neurology & Gastrointestinal Centre of Excellence for Drug Discovery GSK Harlow

  2. Outline of Talk • General Comments on Process • Stroke (chapter written by Eduardo Sabate & Sunil Wimalaratna) • Alzheimer’s Disease (chapter written by Saloni Tanna)

  3. The Burden of Stroke • 1M new strokes p.a. in Europe • 200,000 deaths p.a. in Europe • Estimate of 1.9 million strokes by 2008 (US, Europe, Japan) • Major cause of disability with 1/4 to 1/2 victims requiring dependence

  4. Stroke: Pathophysiology 20% 80%

  5. Issues 1: Current Management • Intervention • Thrombolysis only possible within 3 hours and when haemorrhagic stroke ruled out by scan • Many centres unable to screen patients within the therapeutic window • Most patients don’t present within 3hrs • Previous trials of neuroprotectants have been spectacularly unsuccessful • Supportive care • Specialist stroke centres shown to be of benefit

  6. Issues 2: Lack of New Therapies • Future treatment options divided into:- • Reducing delays • Identification of patients that could respond to specific treatment options • Prolonging treatment window • Late intervention

  7. Patient A DWI @ 3 days Patient B Patient B Patient B MTT @ 6 hrs DWI @ 6 hrs DWI @ 4 days Initial Perfusion Deficits to Identify Patients Patient A Patient A DWI @ 6 hrs MTT @ 6 hrs

  8. Options for Future Research • Prolonging treatment window • ‘Penumbra’ means there is potentially recoverable tissue in many patients • Many mechanisms tried but failure rate high • Clinical trials expensive and prolonged • Late intervention • Potential for regenerative therapies • But endpoints etc poorly defined

  9. Days Weeks/Months Hours >50% patients 14 2 7 8 hrs + Ca Na Glut Enzymes I Necrosis Apoptosis N J Inflammation U Repair R Remodeling Y Plasticity Future Stroke Therapeutic strategies Prevention/Protection Regeneration/FunctionalRecovery Acute Intervention

  10. The Burden of Alzheimer’s Disease • Leading cause of dementia • Affects 18M people world wide • The average duration of disease is 8 years • Direct and indirect costs are estimated in excess of 100 billion dollars per year • No disease modification treatment • No specific diagnostic

  11. Pathological Hallmarks of Alzheimer’s Disease • Senile plaques – toxic b amyloid fibrils • Neurofbrillary Tangles Neurofibrillary tangles Dystrophic neurites Ab Senile plaques

  12. AD and Points of Therapeutic Intervention Abnormal APP metabolism Abnormal phosphorylation of tau b amyloid deposition Neurofibrillary tangles Fibrilisation Plaque formation Cell loss Inflammation (cytokines, free radicals etc) Glucose hypometabolism Neurotransmitter deficits

  13. Issues 1: Diagnosis • No unequivocal diagnosis for AD, especially in early stages • Relationship between MCI and AD • Differential diagnosis from other dementias • Important areas highlighted for research • New imaging agents for amyloid and other diagnostic biomarkers • Improved characterisation of non-cognitive symptoms

  14. Issues 2: Lack of Effective Therapy • Current agents only symptomatic • Cholinesterase inhibitors (mild-moderate) • Memantine (moderate to severe) • Not all patients respond- doses limited by side effects • Focus is on cognitive effects • Management of non-cognitive effects not clear-cut and may further impair cognition

  15. Issue 3: Lack of basic disease understanding • Genetic factors have been identified which have aided disease understanding • Some risk factors have been identified • But lack of basic knowledge means:- • Few validated targets for either symptomatics or disease modification • Animal models essentially pharmacodynamic • Lack of surrogate markers

  16. Potential Disease Modifying Approaches • b secretase • g secretase • Vaccination • Statins • Antioxidants • NSAIDs • Growth factors • Combination therapies will be important

  17. Other Important Gaps • Clinical trial design • Long and costly especially for disease modification • Need reliable predictors of outcome • Guidelines for MCI studies • Encouraging biotech/small pharma to invest in such trials

  18. Summary • Stroke and AD have many similarities • Huge burden which increases with age • Treatment options currently limited • A number of potential treatment options on the horizon • But trials costly and failure rate high- biomarkers/surrogates are critically needed • Ideal diseases for public/private partnership initiatives

  19. BACKUPS

  20. APP processing cascade soluble APP Amyloid Precursor Protein soluble APP N Neuronal cell loss 4 Aggregation   2 3   &  cleavage  site 1 g Soluble Ab (1-40, 1-42)  site Ab domain CELL MEMBRANE  cleavage site (Presenilin-1?) C

  21. GSK’s Comments On The Report • Overall a fairly balanced and helpful report. • Demonstration of dialogue, partnerships and need for combined efforts • Consultation with industry has been very good • Key disease areas identified for focused development and improved treatment. Broad agreement with recommendations, in particular stimulating basic research on areas such as biomarkers • Recognition that the pharmaceutical industry will play a key role in addressing areas of unmet need is helpful and likely to drive partnerships • Focus on reducing barriers to innovation welcome and industry will be looking at ways of taking this forward at a Nhational and European level.

More Related